Section: Pet Parasites

Canine Parasitic Skin Infections: Diagnosis and Treatment Options

Introduction

Canine parasitic skin infections represent a substantial portion of dermatologic cases in small animal practice globally, with prevalence rates varying significantly by geographic region, climate, and vector ecology [49, 81]. These infections are caused by a taxonomically diverse array of organisms including protozoa (e.g. Leishmania spp.), arthropods (e.g. Demodex canis, Sarcoptes scabiei), and filarioid nematodes (e.g. Onchocerca lupi, Cercopithifilaria spp.) [66, 69, 75]. The clinical manifestations of these infections range from localized alopecia and pruritus to severe, systemic disease, necessitating a rigorous diagnostic approach that integrates signalment, history, physical examination, cytology, histopathology, and advanced molecular or serological assays [1, 72, 75]. This article provides an exhaustive review of the etiological agents, diagnostic methodologies, and therapeutic strategies for the most clinically relevant parasitic skin infections in dogs, with an emphasis on evidence-based practice and the biophysical principles underlying diagnostic techniques.

Protozoan Skin Infections

Canine Leishmaniosis

Canine leishmaniosis (CanL), primarily caused by Leishmania infantum (syn. L. chagasi), is a vector-borne, zoonotic disease transmitted by phlebotomine sand flies, and is endemic in the Mediterranean basin, South America, parts of Asia, and increasingly recognized in non-endemic regions due to travel and importation of animals [2, 3, 4, 49]. The disease manifests in a spectrum of clinical forms; dermatological signs are among the most common and include exfoliative dermatitis, ulcerative dermatitis, nodular dermatitis, and onychogryphosis [1, 5, 6, 52]. Ischemic dermatopathy, driven by vasculitis and perivascular inflammation, is a recognized chronic manifestation [6].

Diagnosis of Canine Leishmaniosis

The diagnosis of CanL is multifaceted and relies on a combination of clinical, serological, molecular, and parasitological methods. The World Association for Veterinary Dermatology (WAVD) has published consensus guidelines integrating these modalities [1].

a) Parasitological and Cytological Examination: Direct identification of amastigotes within macrophages in tissue smears, aspirates (lymph node, bone marrow, spleen), or impression smears from skin lesions remains a specific diagnostic method [1, 52]. However, sensitivity is variable and often low, particularly in paucilesional or subclinical cases [55].

b) Serological Assays: Serological detection of anti-Leishmania antibodies is a cornerstone of diagnosis. Several platforms are available:

  • Enzyme-Linked Immunosorbent Assay (ELISA): Widely used for quantitative antibody detection. Recombinant antigens such as rK28, rK39, rKLO8, rKDDR-plus, rDyn-1, and rLicNTPDase-2 have been evaluated for enhanced sensitivity and specificity [46, 86, 109]. The rK28-based ELISA has demonstrated superior accuracy for screening [86]. Novel approaches include double-antigen sandwich homogeneous chemical luminescence assays [51].
  • Indirect Fluorescent Antibody Test (IFAT): A traditional method, though subject to inter-reader variability and cross-reactivity with other trypanosomatids [101].
  • Rapid Lateral Flow Tests: Point-of-care immunochromatographic tests (e.g. using rK39) are available but may have lower sensitivity in dogs with low antibody titers [58].

c) Molecular Diagnostics: PCR-based assays have become essential for confirmation and species differentiation. Quantitative real-time PCR (qPCR) allows quantification of parasite load, which correlates with disease severity and treatment response [7, 41].

  • Conventional PCR and RFLP-PCR: Restriction fragment length polymorphism analysis of amplified DNA (e.g. from the ITS-1 region or the hsp70 gene) enables differentiation of L. infantum, L. tropica, L. major, and L. braziliensis [8, 35, 45].
  • Digital PCR (dPCR): dPCR offers absolute quantification without reliance on standard curves, providing higher sensitivity for detecting low-parasite burden skin infections in chronic dermatitis [9].
  • Lab-on-Chip (LOC) qPCR: Portable platforms allow rapid amplification of L. infantum DNA directly from non-extracted bone marrow, lymph node, and blood samples, with performance comparable to conventional qPCR [94].
  • Tape-Disc LAMP (TD-LAMP): A non-invasive loop-mediated isothermal amplification method using target sequences (e.g. kDNA) from skin material collected via adhesive tape; this has shown high sensitivity and specificity for L. tropica [98].
  • Isothermal assays: Rapid isothermal discrimination protocols for L. braziliensis and L. infantum have been developed for field use [39].

d) Automated Volatile Organic Compound Analysis: An emerging non-invasive approach involves identifying putative volatile biomarkers in exhaled breath and hair using gas chromatography-mass spectrometry coupled with novel algorithms for peak detection and matching [40].

e) Histopathology and In Situ Hybridization: Tissue biopsies can be evaluated using hematoxylin and eosin staining for amastigotes, immunohistochemistry, or colorimetric in situ hybridization (CISH) for detection of parasitic nucleic acids in formalin-fixed, paraffin-embedded tissue [10, 55]. CISH sensitivity is comparable to qPCR for skin samples [55].

Treatment of Canine Leishmaniosis

Therapeutic protocols aim to reduce parasite burden, resolve clinical signs, and restore immune function. The standard of care involves combination therapy with meglumine antimoniate and allopurinol [1, 11]. Monitoring during therapy involves tracking serological titers, inflammatory markers, serum protein electrophoresis, and urinary biomarkers (e.g. urinary amylase to creatinine ratio, Tamm-Horsfall protein) for renal damage [11, 12, 47, 50]. Immunomodulatory protocols using domperidone, mycobacterium cell wall extract, or other agents have been evaluated to reduce parasitemia and proteinuria [41]. In cases of severe glomerulopathy, supportive treatments such as immunoadsorption have been applied experimentally [57]. Topical treatment of skin lesions using biomembranes containing silver nanoparticles and Aloe vera has shown effectiveness in lesion reduction [13]. An isoxazoline, fluralaner, though primarily an arachnicide, has demonstrated efficacy in managing ectoparasitic co-infections, but is not a direct antileishmanial drug [14].

Arthropod Skin Infections

Demodicosis

Canine demodicosis is caused by overpopulation of the commensal mite Demodex canis, and less commonly Demodex injai or Demodex cornei, within hair follicles and sebaceous glands [71, 85]. The disease presents in localized and generalized forms, often complicated by secondary bacterial pyoderma (furunculosis, cellulitis) [71, 99].

Diagnosis of Demodicosis

The gold standard for diagnosis is deep skin scraping of lesional skin, typically performed until capillary bleeding is observed, followed by microscopic visualization of mites, eggs, or larval stages [71, 75, 79]. The trichogram (hair pluck epilation) and adhesive tape impression are useful alternative methods [71, 79]. Cytology of exudative lesions can reveal mites [79]. Histopathological examination of skin biopsies provides definitive confirmation and reveals folliculitis, perifolliculitis, and orthokeratotic hyperkeratosis [99]. Hematological alterations in generalized demodicosis include normocytic normochromic anemia, leukocytosis with neutrophilia or eosinophilia, and an elevated C-reactive protein (CRP) due to inflammation [99, 108]. Oxidative stress markers such as malondialdehyde (MDA) and superoxide dismutase (SOD) are significantly elevated [108].

Treatment of Demodicosis

Therapeutic management focuses on miticidal treatment and resolution of secondary infections:

  • Macrocyclic Lactones: Ivermectin (0.3 to 0.6 mg/kg PO SID, with careful dose escalation), milbemycin oxime, and moxidectin are effective [75]. Isoxazolines (afoxolaner, fluralaner, sarolaner, lotilaner) are highly effective adulticides and ovicides for Demodex.
  • Amitraz: A topical dip (0.025% to 0.05%) used for refractory cases.
  • Antibiotic Therapy: Concurrent pyoderma caused by Staphylococcus spp. requires culture-guided systemic antibiotics based on susceptibility patterns [99, 100].

Sarcoptic Mange (Scabies)

Sarcoptic mange is a highly contagious, intensely pruritic dermatitis caused by the burrowing mite Sarcoptes scabiei var. canis [75, 92]. The mite burrows in the stratum corneum, eliciting a severe type IV hypersensitivity response. Lesions typically involve the pinnae margins, elbows, and ventral abdomen.

Diagnosis of Sarcoptic Mange

Definitive diagnosis relies on demonstration of mites, eggs, or fecal pellets via deep skin scraping, though sensitivity is low (20-50%) due to the small number of mites [92, 106]. Alternative methods include:

  • Dermatoscopy: In vivo visualization of triangular-shaped mites (delta wing sign) embedded in the skin [73, 92].
  • Adhesive Tape Test: Collection of mites from burrow openings, with higher sensitivity than scraping (up to 70%) [92].
  • Serology: ELISA detection of IgG antibodies against Sarcoptes antigens has shown higher sensitivity than skin scraping [92].
  • PCR: PCR from skin scrapings or even from fecal samples is highly specific but not universally available [92].
  • Therapeutic Trial: A rapid response to an isoxazoline (e.g. afoxolaner, fluralaner, sarolaner) is considered strong supportive evidence [14, 15, 75].

Treatment of Sarcoptic Mange

Modern treatments utilize macrocyclic lactones (moxidectin, selamectin) or, more commonly, oral isoxazolines (afoxolaner, fluralaner, sarolaner), which achieve high efficacy after a single dose or two doses [14, 15]. Fluralaner, in particular, has shown exceptional field efficacy when used in a combined ectoparasiticide formulation [14]. All in-contact animals require treatment.

Otodectic Mange

Caused by Otodectes cynotis, ear mites are a common cause of otitis externa and pruritic dermatitis in dogs, especially puppies. Diagnosis is via otoscopic visualization of mites or microscopic examination of cerumen. Treatment involves topical acaricidal otic preparations, or systemic isoxazolines [14].

Filarioid Nematodes

Onchocerca lupi and Subcutaneous Filarioids

Onchocerca lupi is an emerging zoonotic filarioid that causes ocular and periorbital lesions in dogs [16, 66, 76, 104]. The adult worms reside in subcutaneous granulomas, while microfilariae are found in the dermis. Cercopithifilaria spp. (e.g. C. bainae, C. grassii) are dermal microfilariae transmitted by ticks, often subclinical or causing mild dermatitis [66, 76].

Diagnosis of Filarioid Infections

Diagnosis is challenging:

  • Skin Snips and Biopsies: Microfilariae can be visualized in skin biopsies or from expressed dermal fluid [66].
  • Modified Knott’s Test: For blood-borne filarioids (e.g. Dirofilaria immitis), but not for dermal filarioids [76].
  • Multiplex qPCR: Novel molecular approaches targeting filarial and Cercopithifilaria cox1 sequences from skin, blood, or engorged ticks allow high-throughput, species-specific detection [76]. Paramyosin-based serological assays are under development for O. lupi [104].
  • Histology: Sectioning of granulomas reveals adult nematodes embedded in dense connective tissue [104].

Treatment of Filarioid Infections

Surgical excision remains the standard for O. lupi. No reliable macrofilaricidal protocol currently exists. Microfilaricidal treatment with macrocyclic lactones (e.g. ivermectin, moxidectin) may be attempted, though efficacy is variable [66, 105].

Deep Fungal Mimics and Other Parasites

Tungiasis, caused by the sand flea Tunga penetrans and Tunga trimamillata, can present as nodular pedal lesions in dogs in endemic areas [17]. Prototheca spp. are algae that can mimic nodular dermatitis in immunocompromised dogs co-infected with Ehrlichia canis or Hepatozoon canis [38]. Diagnosis of these requires histopathology with specific stains (PAS, GMS for algae) and molecular identification.

Diagnostic Workflow and Decision Tree

A systematic diagnostic approach is critical for managing canine parasitic skin infections. The following Mermaid diagram illustrates a generalized diagnostic workflow.

flowchart TD
    A[Pruritus, Alopecia, Papules, Crusts] --> B[Signalment, History, Environmental Risk]
    B --> C{Primary Dermatologic Examination}
    C --> D[Deep Scraping + Trichogram + Acetate Tape]
    D --> E[Mites visualized?]
    E -- Yes --> F[Demodicosis / Sarcoptic / Otodectic]
    E -- No --> G[Compilation of rule-outs]
    G --> H[Endemic Leishmania region?]
    H -- Yes --> I[Serology + qPCR / dPCR]
    I --> J[Serology + PCR positive?]
    J -- Yes --> K(Canine Leishmaniosis)
    H -- No --> L[Filarioid / Onchocerca endemic?]
    L -- Yes --> M[Skin snips + Multiplex qPCR for filarioids]
    M --> N[Positive?]
    N -- Yes --> O(Onchocerca / Cercopithifilaria)
    N -- No --> P[Fungal / Bacterial culture + Biopsy]
    P --> Q[Histology + Special stains]
    Q --> R[Protothecosis / Deep Mycoses / Neoplasia]
    K --> S[Staging + Treatment]
    F --> T[Localized vs Generalized]
    T --> U["Localized: topical / oral therapy"]
    T --> V["Generalized: systemic therapy + antibiotics for pyoderma"]
    U --> W[Resolution]
    V --> W
    S --> W
    O --> X[Consider surgical excision for nodules]
    X --> W

Emerging Diagnostic Technologies

Several emerging technologies are enhancing diagnostic accuracy and turnaround times for parasitic skin infections:

  • High-Throughput Sequencing (HTS): Next-generation sequencing of the hsp70 gene (or other barcoding loci) enables precise identification of Leishmania species from clinical samples, including New World species [62].
  • Quantitative PCR (qPCR) from Non-Extracted Samples: Point-of-care LOC platforms allow direct amplification from biological fluids, bypassing DNA extraction steps [94].
  • Deep Learning for Image Classification: Convolutional neural networks (e.g. InceptionV3, MobileNetV2) have been trained to classify images of skin lesions (dermatophytosis, demodicosis, pyoderma, leishmaniosis) with accuracy exceeding 95%, though clinical integration remains nascent [95].
  • LAMP and RPA: Isothermal amplification methods are ideal for field deployment and low-resource settings, with colorimetric readouts providing clear visual confirmation [98].

Conclusion

Canine parasitic skin infections present a complex diagnostic landscape requiring integration of clinical, paraclinical, and advanced molecular methods. Leishmaniosis remains the most clinically significant, with robust serological and molecular assay protocols now available. Mange and filarioid infections benefit from improved diagnostic sensitivity through dermatoscopy, multiplex qPCR, and isothermal amplification. Treatment strategies have advanced with the availability of isoxazoline ectoparasiticides, targeted antileishmanial protocols, and supportive topical therapies. A rigorous, evidence-based approach reduces morbidity, limits zoonotic risk, and improves patient outcomes.

Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.

References

[1] Saridomichelakis MN, Baneth G, Colombo S et al. World Association for Veterinary Dermatology Consensus Statement for Diagnosis, and Evidence-Based Clinical Practice Guidelines for Treatment and Prevention of Canine Leishmaniosis. Vet Dermatol. 2025. https://pubmed.ncbi.nlm.nih.gov/40745695/

[2] Miranda LFC, Coelho LFDR, Xavier SCDC et al. Canine Leishmaniasis in Rio de Janeiro, Brazil (2000-2015): Taxonomic Characterisation of Etiological Agents and Geospatial Case Analysis. Zoonoses Public Health. 2026. https://pubmed.ncbi.nlm.nih.gov/41813617/

[3] Kent SC, O'Neill DG, Stevens KB et al. The frequency, risk factors and spatial distribution associated with having a diagnosis of leishmaniosis in dogs in the UK in 2019. PLoS One. 2026. https://pubmed.ncbi.nlm.nih.gov/41779685/

[4] Baneth G, Peri Markovich M, Nachum-Biala Y et al. Retrospective study of canine leishmaniosis in Israel. Parasit Vectors. 2025. https://pubmed.ncbi.nlm.nih.gov/40615842/

[5] Gernone F, Otranto D, Mendoza-Roldan JA et al. Canine leishmaniosis and peripheral neuropathy: a lesson from the neurologist. Parasit Vectors. 2025. https://pubmed.ncbi.nlm.nih.gov/40500785/

[6] García N, Cobos À, Solano-Gallego L et al. Clinical, Immunological and Pathological Characteristics of Ischemic Dermatopathy in Dogs with Leishmaniosis. Pathogens. 2025. https://pubmed.ncbi.nlm.nih.gov/40137731/

[7] Sarquis J, Sanz CR, Raposo LM et al. Unveiling prognostic indicators in canine leishmaniosis: two decades of evidence. Parasit Vectors. 2025. https://pubmed.ncbi.nlm.nih.gov/41254814/

[8] Rihs JB, Vilela MT, Coelho Dos Santos JS et al. A qPCR-based strategy for differential diagnosis of visceral and cutaneous leishmaniasis in humans and dogs. Acta Trop. 2026. https://pubmed.ncbi.nlm.nih.gov/41610969/

[9] Brustenga L, Brachelente C, Morganti G et al. Diagnostic value of digital PCR (dPCR) in the diagnosis of leishmania infantum from canine chronic dermatitis. Res Vet Sci. 2026. https://pubmed.ncbi.nlm.nih.gov/42107337/

[10] Escobar ST, Petronic-Rosic V. Clinical, histopathologic, and immunohistochemical patterns of cutaneous leishmaniasis. Clin Dermatol. 2025. https://pubmed.ncbi.nlm.nih.gov/41043653/

[11] Giner J, González A, Lebrero ME et al. Changes in serological, inflammatory, and serum protein electrophoretic markers during ongoing meglumine antimoniate plus allopurinol therapy in canine leishmaniosis. Vet Res Commun. 2026. https://pubmed.ncbi.nlm.nih.gov/42142214/

[12] Pantaleo V, Furlanello T, Ventura L et al. Evaluation of urinary amylase to creatinine ratio alone and in combination with urinary electrophoresis as a marker of renal damage in dogs with leishmaniosis undergoing conventional anti-Leishmania treatment. Res Vet Sci. 2026. https://pubmed.ncbi.nlm.nih.gov/41955684/

[13] Batista DDCS, de Oliveira MR, de Jesus JV et al. Effectiveness of Aloe vera (L.) Burm.F. biomembranes with silver nanoparticles in the clinical experimental treatment of skin lesions of dogs with leishmaniasis. Microb Pathog. 2025. https://pubmed.ncbi.nlm.nih.gov/40446971/

[14] Cruz BC, Teixeira MB, de Melo Cruz GA et al. Efficacy of a fluralaner-based ectoparasiticide for the control of otodectic and sarcoptic mange in naturally infested dogs, evaluated in randomized, double-blind clinical studies. Parasit Vectors. 2026. https://pubmed.ncbi.nlm.nih.gov/41724992/

[15] Antoine L, Papadopoulos E, Sioutas G et al. Field efficacy assessment of a combination of afoxolaner, moxidectin and pyrantel pamoate to treat dogs naturally infested with Sarcoptes scabiei. Parasite. 2026. https://pubmed.ncbi.nlm.nih.gov/41568903/

[16] Kelly MA, Clarke E, Hakimi H et al. Prevalence of Onchocerca lupi in shelter dogs from an endemic region of the Southwestern USA. Parasit Vectors. 2025. https://pubmed.ncbi.nlm.nih.gov/40764591/

[17] Chaguay Villamar KM, Hernández Copello VM, Toro-Valdivieso C et al. First report of Tunga trimamillata infection in a dog. BMC

[18] Sánchez MD, Clément N, Cailleau A et al. Comparison of three culture media for testing susceptibility of Malassezia pachydermatis to four antifungal agents by a microdilution method and gradient diffusion strips. Med Mycol. 2026. https://pubmed.ncbi.nlm.nih.gov/41995296/

[19] Archbold K, Pineda V, Calzada JE et al. Using Bayesian methods to evaluate the diagnostic performance of blood-based diagnostic tests for American cutaneous leishmaniasis and Chagas disease in rural Panamanian dogs in the absence of a gold standard. Vet Parasitol. 2026. https://pubmed.ncbi.nlm.nih.gov/41962193/

[20] Murillo A, Lebrero ME, Valdés M et al. Post-surgical seroreversion in a case of equine cutaneous leishmaniosis by Leishmania infantum. Vet Res Commun. 2026. https://pubmed.ncbi.nlm.nih.gov/41504811/

[21] Foglia Manzillo V, Balestrino I, Oliva G et al. High Seroprevalence of Feline Leishmaniosis (FeL) in Campania (Italy) Region: Current Epidemiological Scenario. Pathogens. 2025. https://pubmed.ncbi.nlm.nih.gov/41471150/

[22] Hananeh W, Al Rukibat R, Hammad H et al. Review of animal leishmaniosis in Jordan: An alarming discovery with implications for public health and animal welfare. Vet Parasitol Reg Stud Reports. 2025. https://pubmed.ncbi.nlm.nih.gov/41354537/

[23] Kaya T, Özbilgin A, Çulha G et al. Investigation of the Canine Leishmaniasis in Hatay/Turkey. Vet Parasitol Reg Stud Reports. 2025. https://pubmed.ncbi.nlm.nih.gov/41354519/

[24] Dinkova V, Rusenova N. Prevalence of Malassezia pachydermatis yeasts in clinical infections in dogs: A single-center retrospective study at the University Veterinary Hospital, Stara Zagora, Bulgaria (2019-2023). Open Vet J. 2025. https://pubmed.ncbi.nlm.nih.gov/41200355/

[25] Haber GZ, da Costa LD, Costa EBM et al. Specificity of Primers and Probes for Molecular Diagnosis of Leishmania (Leishmania) chagasi in Dogs and Wild Animals. Pathogens. 2025. https://pubmed.ncbi.nlm.nih.gov/41156675/

[26] Oliveira CF, Oliveira PLN, Nascimento JNDS et al. Anti-Toxoplasma gondii and Leishmania spp. antibodies in household and shelter dogs in the municipality of Arapiraca, Alagoas, Northeastern Brazil. Vet Parasitol Reg Stud Reports. 2025. https://pubmed.ncbi.nlm.nih.gov/40803810/

[27] Cavalera MA, Uva A, Carbonara M et al. Seasonal variation of anti-Leishmania infantum antibodies and laboratory abnormalities in dogs with leishmaniosis. Parasit Vectors. 2025. https://pubmed.ncbi.nlm.nih.gov/40751264/

[28] Scorza BM, Pessôa-Pereira D, Pabon-Rodriguez F et al. Tick-borne coinfections modulate CD8(+) T cell response and progressive leishmaniosis. Infect Immun. 2025. https://pubmed.ncbi.nlm.nih.gov/40741972/

[29] Saini P, Sivalaxmi B, Haritha HA et al. Molecular detection of Leishmania donovani, Dirofilaria sp. "hongkongensis," and Wolbachia spp. in the dog population from tribal settlements of Western Ghats, Kerala, India. Parasitol Res. 2025. https://pubmed.ncbi.nlm.nih.gov/40338373/

[30] Verçosa BLA, Muniz-Junqueira MI, Borges LF et al. Enhanced apoptosis, inflammatory cellularity, collagen deposition, and interaction between fibroblasts and Leishmania amastigotes in undamaged ear skin of dogs with leishmaniosis. Vet Parasitol. 2025. https://pubmed.ncbi.nlm.nih.gov/40315687/

[31] da Silva Santos IC, de Avelar DM, Miranda LFC et al. Autochthonous Leishmania (Viannia) lainsoni in Dog, Rio de Janeiro State, Brazil, 2023. Emerg Infect Dis. 2025. https://pubmed.ncbi.nlm.nih.gov/40305420/

[32] Chambaro HM, Hayashida K, Moonga LC et al. A high prevalence of dogs seropositive to Leishmania in Zambia. Parasitol Int. 2025. https://pubmed.ncbi.nlm.nih.gov/40286866/

[33] Güler E, Özbilgin A, Çavuş İ et al. [Molecular Characterization of Cutaneous Leishmaniasis and Canine Leishmaniasis Strains Isolated from Northern Cyprus and Their Clinical Reflections in Mice Models]. Mikrobiyol Bul. 2025. https://pubmed.ncbi.nlm.nih.gov/40277267/

[34] González MA, Barrera-Chacón R, Jiménez J et al. New biomarkers and scintigraphic evaluation of renal function in dogs with canine leishmaniosis. Res Vet Sci. 2025. https://pubmed.ncbi.nlm.nih.gov/40022866/